Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment

Edesa Biotech Inc. (NASDAQ:EDSA) is one of the 10 Unstoppable Stocks That Could Double Your Money.

Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is on track to begin in mid-2026. The company has selected JSS Medical Research as its clinical research organization and has initiated outreach to potential clinical sites. Recruitment is expected to start at investigational sites in Canada, following the approval of the company’s clinical trial application.

The upcoming study will evaluate the safety and efficacy of EB06, a monoclonal antibody designed to target the chemokine CXCL10, which plays a critical role in the destruction of skin pigment cells. By neutralizing this protein, EB06 aims to prevent and reverse the depigmentation associated with vitiligo. The CEO emphasized that the trial design has been refined through discussions with key opinion leaders to address the significant need for effective systemic therapeutics in a market with few approved options.

Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment

Photo by RephiLe water on Unsplash

EB06 has already shown biological activity and a favorable safety profile in three previous clinical studies involving 65 subjects. While the current Phase 2 trial will use an intravenous formulation, Edesa Biotech Inc. (NASDAQ:EDSA) is also developing a subcutaneous version for future clinical evaluation.

Edesa Biotech Inc. (NASDAQ:EDSA) is a clinical-stage biotech company that was founded in 2015. The company researches, develops, manufactures, and commercializes products for inflammatory and immune-related diseases.

While we acknowledge the risk and potential of EDSA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EDSA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.